The effect of SGLT2 inhibition on prostate cancer: Mendelian randomization and observational analysis using electronic healthcare and cohort data
Zheng J., Lu J., Qi J., Yang Q., Zhao H., Liu H., Chen Z., Huang L., Ye Y., Xu M., Xu Y., Wang T., Li M., Zhao Z., Zheng R., Wang S., Lin H., Hu C., Ling Chui CS., Au Yeung SL., Luo S., Dimopoulou O., Dixon P., Harrison S., Liu Y., Robinson J., Yarmolinsky J., Haycock P., Yuan J., Lewis S., Yuan Z., Gaunt TR., Smith GD., Ning G., Martin RM., Cui B., Wang W., Bi Y.
We evaluated the effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on prostate cancer by evidence triangulation. Using Mendelian randomization, we found that genetically proxied SGLT2 inhibition reduced the risk of overall (odds ratio = 0.56, 95% confidence interval [CI] = 0.38 to 0.82; 79,148 prostate cancer cases and 61,106 controls), advanced, and early-onset prostate cancer. Using electronic healthcare data (nSGLT2i = 24,155; nDPP4i = 24,155), we found that the use of SGLT2 inhibitors was associated with a 23% reduced risk of prostate cancer (hazard ratio = 0.77, 95% CI = 0.61 to 0.99) in men with diabetes. Using data from two prospective cohorts (n4C = 57,779; nUK_Biobank = 165,430), we found little evidence to support the association of HbA1c with prostate cancer, implying a non-glycemic effect of SGLT2 inhibition on prostate cancer. In summary, this study provides multiple layers of evidence to support the beneficial effect of SGLT2 inhibition on reducing prostate cancer risk. Future trials are warranted to investigate whether SGLT2 inhibitors can be recommended for prostate cancer prevention.